Patents by Inventor Christian Klein

Christian Klein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11965825
    Abstract: The present disclosure relates to an in-line compact measuring device, for example for optical measurements, comprising a housing having a process connection intended to be connected to a process vessel connection complementary to the process connection; at least one sensor assembly arranged in the housing; and a measuring circuit that is connected to the sensor assembly and is arranged in the housing. The in-line compact measuring device has at least one fluid line in thermally conductive contact with at least one housing wall of the housing, which fluid line can be connected to a cooling fluid supply arranged outside the housing.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: April 23, 2024
    Assignee: Endress+Hauser Conducta GmbH+Co. KG
    Inventors: Hongshuo Domnick, Christian Cramer, Michael Wiederkehr, Moritz Klein, Joachim Mannhardt
  • Publication number: 20240117049
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: August 29, 2023
    Publication date: April 11, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria AMANN, Juergen Peter BACHL, Alexander BUJOTZEK, Carina CANTRILL, Harald DUERR, Janine FAIGLE, Sabine IMHOF-JUNG, Christian KLEIN, Thomas KRAFT, Estelle MARRER-BERGER, Ekkehard MOESSNER, Laurene POUSSE, Petra RUEGER, Johannes SAM, Roland STAACK, Dietrich TUERCK, Pablo UMANA, Joerg ZIELONKA
  • Patent number: 11952421
    Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: April 9, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
  • Publication number: 20240108616
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: November 10, 2023
    Publication date: April 4, 2024
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • Publication number: 20240109976
    Abstract: The present invention relates to combination therapies employing anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1 BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: June 13, 2023
    Publication date: April 4, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Claudia Ferrera Koller, Christian Klein, Mario Perro, Johannes Sam, Pablo Umaña, Wei Xu
  • Publication number: 20240092853
    Abstract: The present invention generally relates to pH-dependent mutant interleukin-2 polypeptides that exhibit reduced IL-2 receptor binding at neutral pH and retained IL-2 receptor binding at reduced pH. In addition, the invention relates to immunoconjugates comprising said pH-dependent mutant IL-2 polypeptides, polynucleotide molecules encoding the pH-dependent mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the pH-dependent mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: December 2, 2021
    Publication date: March 21, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lorenzo DEHO, Christian GASSNER, Sylvia HERTER, Thomas HOFER, Ralf HOSSE, Adrian HUGENMATTER, Christian KLEIN, Florian LIMANI, Ekkehard MOESSNER, Melanie OBBA, Bianca SCHERER, Pablo UMANA
  • Publication number: 20240092856
    Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunoconjugates with specific antibodies which bind human FAP and 4-1BB and optionally with an anti-CEA/anti-CD3 bispecific antibody.
    Type: Application
    Filed: March 8, 2022
    Publication date: March 21, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Christina CLAUS, Laura CODARRI DEAK, Sara COLOMBETTI, Christian KLEIN, Valeria G. NICOLINI, Mario PERRO, Johannes SAM, Christine TRUMPFHELLER, Pablo UMAÑA
  • Publication number: 20240082437
    Abstract: The present invention relates to antibodies which bind to antigens on target cells and which target effector moieties to said cells, and to methods of using the same.
    Type: Application
    Filed: January 10, 2022
    Publication date: March 14, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian KLEIN, Alexander HAAS, Sabine IMHOF-JUNG, Sofia FROST
  • Publication number: 20240067749
    Abstract: The present invention generally relates to antibodies that bind to GPRC5D, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: April 28, 2023
    Publication date: February 29, 2024
    Inventors: GEORG FERTIG, CHRISTIAN KLEIN, STEFAN LORENZ, WEI XU, MARIE-LUISE BERNASCONI, ALEXANDER BUJOTZEK
  • Publication number: 20240067734
    Abstract: The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: October 24, 2023
    Publication date: February 29, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Guy GEORGES, Ralf HOSSE, Inja WALDHAUER, Christian KLEIN, Pablo UMANA
  • Patent number: 11915671
    Abstract: Techniques for providing adaptive assistive technology for assisting users with visual impairment can be used on a computing device. These techniques include displaying content to a user, capturing a series of images or video of the user using a camera, analyzing the series of images or video to determine whether the user is exhibiting behavior or characteristics indicative of visual impairment, and rendering a magnification user interface on the display configured to magnify at least a portion of the content of the display based on a determination that the user is exhibiting behavior or characteristics indicative of visual impairment. The magnification user interface may be controlled based on head and/or eye movements of the user of the computing device.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: February 27, 2024
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Jason A. Grieves, Eric N. Badger, Grant M. Wynn, Paul J. Olczak, Christian Klein
  • Publication number: 20240058443
    Abstract: The present invention relates to the prevention or mitigation of adverse effects related to NK cell engaging agents, such as cytokine-related infusion reactions. Specifically, the invention relates to the prevention or mitigation of such side effects using an inhibitor of Src, JAK and/or mTOR.
    Type: Application
    Filed: October 20, 2023
    Publication date: February 22, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hélène Cécile HAEGEL, Christian KLEIN, Gabrielle LECLERCQ, Alberto TOSO, Tina ZIMMERMANN
  • Publication number: 20240043535
    Abstract: The present invention generally relates to novel immune activating Fc domain binding molecules for activation of immune cells and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: December 16, 2022
    Publication date: February 8, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Alejandro Carpy Gutierrez Cirlos, Christina Claus, Laura Codarri Deak, Diana Darowski, Tanja Fauti, Claudia Ferrara Koller, Anne Freimoser-Grundschober, Sylvia Herter, Thomas Hofer, Christian Klein, Laura Lauener, Stephane Leclair, Ekkehard Moessner, Christiane Neumann, Pablo Umaña, Ali Bransi, Marlena Surówka
  • Patent number: 11865082
    Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-L1.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: January 9, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Douglas Hanahan, Christian Klein, Valeria Nicolini, Pablo Umana, Stephan Wullschleger
  • Publication number: 20240002546
    Abstract: The invention relates to combination therapies employing anti-PD1/anti-LAG3 bispecific antibody and a CD20 T cell-activating bispecific antibody, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: July 5, 2023
    Publication date: January 4, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Christian Klein, Mario Perro, Patrick Alexander Aaron Weber
  • Publication number: 20240000776
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: September 7, 2023
    Publication date: January 4, 2024
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • Publication number: 20240002506
    Abstract: The present invention relates to anti-LAG3 antibodies, to methods of producing these molecules and methods of using the same.
    Type: Application
    Filed: June 20, 2023
    Publication date: January 4, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura CODARRI DEAK, Stefan C. DENGL, Jens FISCHER, Christian KLEIN, Stefan SEEBER, Patrick Alexander Aaron WEBER, Adrian ZWICK
  • Publication number: 20230416411
    Abstract: The present invention generally relates to bispecific antibodies that bind to CD3 and Folate Receptor 1 (FolR1), e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: December 15, 2022
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Martina GEIGER, Christian KLEIN, Alexander KNAUPP
  • Publication number: 20230416365
    Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: November 17, 2022
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guy GEORGES, Thomas HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Pablo UMAÑA, Jenny THOM, Stephan GASSER, Jean-Baptiste VALLIER, Tanja FAUTI
  • Publication number: 20230416366
    Abstract: The present invention relates to anti-CD3/anti-CD28 bispecific antigen binding molecules and masked protease activated forms thereof, methods for their production, pharmaceutical compositions containing these molecules, and their use as immunomodulators and/or costiumulators in the treatment of a disease, in particular cancer.
    Type: Application
    Filed: December 21, 2022
    Publication date: December 28, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Martina GEIGER, Thomas HOFER, Christian KLEIN, Pablo UMAÑA